Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 11Recruiting 5Terminated 3Unknown 2Active not recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 62Carcinoma, Non-Small-Cell Lung 45Triple Negative Breast Neoplasms 24Ovarian Neoplasms 20Fallopian Tube Neoplasms 17Neoplasm Metastasis 16Lung Neoplasms 16Endometrial Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 12Esophageal Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 7Inflammatory Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Carcinoma, Ovarian Epithelial 5Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Lung Diseases 3

Interventions

pembrolizumab 4Oxaliplatin 4zolbetuximab 2camrelizumab 2apatinib 2S 1 (combination) 2Paclitaxel 2Nivolumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1tepotinib 1relugolix 1regorafenib 1lenvatinib 1durvalumab 1dabrafenib 1cemiplimab 1cabazitaxel 1alpha-2'-deoxythioguanosine 1X-Rays 1Vinorelbine 1Trifluridine 1Surveys and Questionnaires 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma × Paclitaxel × Clear all
NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡